Opinion

Video

Multidisciplinary Approaches in PSMA PET for Prostate Cancer

Author(s):

Brian Helfand, MD, PhD,Brian Chapin, MD

Dr Helfand and panelists outline the incorporation of multidisciplinary approaches to the management of prostate cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      Laura Davis, MD, on persistent poverty and early onset prostate cancer
      Laura Davis, MD, on persistent poverty and early onset prostate cancer
      Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
      Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
      Ruben Olivares, MD, answers a question during a Zoom video interview
      Ruben Olivares, MD, discusses HIFU and remote prostate cancer care
      Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
      Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
      Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
      Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
      Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
      Post-RP incontinence: Low procedure rates examined
      Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
      Data link incontinence severity to post-radical prostatectomy care
      Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
      Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
      Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
      Expert discusses differentiating prostate cancer from age-related issues
      Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
      Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
      Related Content
      CMS issues reimbursement code for PSMA-PET imaging agent Gozellix
      July 15th 2025

      CMS issues reimbursement code for PSMA-PET imaging agent Gozellix

      Hannah Clarke
      The level II code A9616 will be effective starting on October 1, 2025.
      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
      April 27th 2025

      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

      Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
      Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
      Study shows favorable outcomes with guideline-based treatment for localized prostate cancer
      July 14th 2025

      Study shows favorable outcomes with guideline-based treatment for localized prostate cancer

      Hannah Clarke
      “Our data support adherence to guideline recommendations for treatment of prostate cancer,” says Pietro Scilipoti, MD.
      Dr. Murphy on increasing diversity in cancer clinical trials
      February 29th 2024

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
      Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
      July 10th 2025

      EMBARK: Significant OS gains seen with enzalutamide plus leuprolide in nmHSPC

      Benjamin P. Saylor
      According to the news release, detailed OS data from EMBARK are set to be presented at an upcoming medical conference.
      FDA grants fast track designation to TRE-515 with 177Lu-PSMA-617 for mCRPC
      July 9th 2025

      FDA grants fast track designation to TRE-515 with 177Lu-PSMA-617 for mCRPC

      Benjamin P. Saylor Hannah Clarke
      The investigational treatment is being evaluated in phase 1 clinical trials for solid tumors.
      © 2025 MJH Life Sciences

      All rights reserved.